Sue Visit 3 - A 34-Year-Old Woman With Newly Diagnosed Psoriatic Arthritis Starting Therapy
| Title: | Sue Visit 3 - A 34-Year-Old Woman With Newly Diagnosed Psoriatic Arthritis Starting Therapy |
| Topic: | Dermatology |
| Relevant Terms: | Rheumatology |
| Primary Audience: | Dermatologists, Rheumatologists |
| Launch Date: | 03-Dec-09 |
| Credits: | 0.5 AMA PRA Category 1 Credit™ 0.5 AANP contact hour of continuing education 0.5 AAPA Category 1 Credit |
| Expiration Date: | The accreditation for this activity has expired. |
Learning Objectives
Upon completion of the activity, participants should be able to:
- Select systemic therapies for psoriatic arthritis considering varying severity of cutaneous and musculoskeletal manifestations; monitor these therapies for safety and efficacy
- Compare and contrast treatment approaches for cutaneous and musculoskeletal manifestations of psoriatic arthritis
- Identify and manage comorbidities in patients with psoriatic arthritis
Faculty
Activity Director
Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of
Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Orthopedic & Rheumatologic Institute
Cleveland Clinic
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
DIME Editor
Scientific Director
DIME
Chicago, Illinois
Target Audience
This activity is targeted to rheumatologists and dermatologists with an interest in psoriatic arthritis.
Activity Purpose
The purpose of this activity is to focus on defining the optimal management of psoriatic arthritis from both a dermatology and rheumatology perspective.
Statement of Need
Psoriatic arthritis (PsA) is a progressive inflammatory spondyloarthropathy that leads to significant disability and diminished quality of life if the disease goes unrecognized or is suboptimally treated. Treatment decisions must account for cutaneous and musculoskeletal involvement, and optimally there would be close collaboration between dermatologists and rheumatologists to diagnose and manage these patients. Signs of PsA may go unrecognized and clinicians and patients with psoriasis may be unaware of the significance of early nonspecific symptoms. Treatment decisions for PsA are complicated by its heterogeneity and the involvement of multiple organ systems. The associated cutaneous and joint manifestations require individualized treatment regimens due to divergent responses to treatment. Practice improvements, including timely diagnosis and better management of patient quality of life and morbidity, along with optimized treatment, may help improve the outlook for patients with PsA.
Faculty Disclosures
Current guidelines state that participants in CME/CE activities should be made aware of any affiliation or financial interest that may affect those involved with content development. Those persons have completed a Statement of Disclosure, and their names and relevant information will appear in the course materials. This information is used to: (1) determine whether a conflict exists, (2) resolve the conflict by initiating a content validation process, and (3) advise learners of this information.
This CE activity may include discussions regarding the use of medications that may be outside the approved labeling for these products. Prescribing clinicians should consult the current prescribing information for these products. DIME requires the speaker to disclose that the product is not labeled for the use under discussion. Compliance is documentation that demonstrates the provider has a practice in place to make this requirement known to the faculty.
Faculty
M. Elaine Husni, MD, MPH
Sources of Funding for Research: Pfizer Inc; Roche Laboratories, Inc.
Consulting Agreements: Amgen Inc.; Genentech, Inc.; UCB; Wyeth Pharmaceuticals
Financial Interests/Stock Ownership: None
Speakers' Bureau/Honorarium Agreements: None
Discussion of Off-Label, Investigational or Experimental Drug Use: None
Faculty
Abrar Qureshi, MD, MPH
Sources of Funding for Research: None
Consulting Agreements: None
Financial Interests/Stock Ownership: None
Speakers' Bureau/Honorarium Agreements: None
Discussion of Off-Label, Investigational or Experimental Drug Use: None
Activity Director
Leonard Calabrese, DO
Sources of Funding for Research: Centocor Inc.
Consulting Agreements: Abbott Laboratories; Amgen Inc.; Centocor, Inc.; Elan; Genentech Inc.; Roche Laboratories, Inc.
Financial Interests/Stock Ownership: None
Speakers' Bureau/Honorarium Agreements: Amgen Inc.; Genentech Inc.
Discussion of Off-Label, Investigational or Experimental Drug Use: None
DIME Editor
Denise Erkkila, RPh
Sources of Funding for Research: None
Consulting Agreements: None
Financial Interests/Stock Ownership: None
Financial Interests/Stock Ownership: None
Speakers' Bureau/Honorarium Agreements: None
Discussion of Off-Label, Investigational or Experimental Drug Use: None
The activity content was developed independently by the contributing faculty or editors. The materials included in this activity have undergone peer review by the chairperson(s) or editor(s). All materials are included with the permission of the authors. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
CME Accreditation Statement
DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Designation Statement
DIME designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AAPA Category 1 CME Credit
This program has been reviewed and is approved for a maximum of 0.50 hours of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Approval is valid for 1 year from the issue date of December 3, 2009. Participants may submit the self-assessment at any time during that period.
This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

AAPA Category 1 CME Credit
This program has been reviewed and is approved for a maximum of 0.50 hours of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Approval is valid for 1 year from the issue date of December 3, 2009. Participants may submit the self-assessment at any time during that period.
This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
AANP Contact Hours
This program is approved for 0.50 contact hour(s) of continuing education by the American Academy of Nurse Practitioners. Program ID: 0911395. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
Support Statements
Support Statements

This activity has been developed in cooperation with The Cleveland Clinic Foundation Center for Continuing Education.

Supported by the National Psoriasis Foundation as an Approved Education Partnership as it helps to improve the quality of life for people with psoriasis and psoriatic arthritis. The National Psoriasis Foundation is a nonprofit organization that does not recommend or endorse any specific treatment or product for psoriasis or psoriatic arthritis. This program was reviewed, but not developed by, the Foundation.
How to Receive Credit
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the posttest and activity evaluation.
- Physicians who successfully complete the posttest and evaluation will receive CME credit. Successful completion is defined as a cumulative score of at least 70% correct.
- All other participants who successfully complete the posttest and evaluation will receive a certificate of participation.
|
PC
Internet Explorer (v6 or greater), or Firefox |
MAC Safari |
Release Date: December 3, 2009
Expiration Date: December 3, 2010
Acknowledgment
Supported by an educational donation provided by Amgen Inc.

This continuing medical education activity is sponsored by DIME.



